Ulcerative colitis exacerbating after placement of intragastric balloon for the treatment of obesity

Inflammatory Bowel Diseases

Volumn 14, Issue 6, 2008, Pages 872-873

  Manguso, Francesco ^a   Picascia, Salvatore ^a   Balzano, Antonio ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; BALLOON; CASE REPORT; DIARRHEA; DISEASE EXACERBATION; FEMALE; HUMAN; LETTER; MORBID OBESITY; NAUSEA; PRIORITY JOURNAL; SIGMOIDOSCOPY; ULCERATIVE COLITIS; VOMITING;

ADULT; COLITIS, ULCERATIVE; FEMALE; GASTRIC BALLOON; HUMANS; OBESITY, MORBID;

EID: 46049094678     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20373     Document Type: Letter

References (13)

1. Das U. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
2. Cottam D, Mattar S, Barinas E. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004;14:589-600.
3. Laimer M, Ebenbichler CF, Kaser S. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes. 2002;26:659-662.
4. Lascano CA, Soto F, Carrodeguas L, et al. Management of ulcerative colitis in the morbidly obese patient: is bariatric surgery indicated? Obes Surg. 2006;16:783-786.
5. Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101-105.
6. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19-27.
7. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
8. Bonazzi P, Petrelli MD, Lorenzini I, et al. Gastric emptying and intragastric balloon in obese patients. Eur Rev Med Pharmacol. Sci 2005;9(Suppl 1):15-21.
9. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv. 2006;3:111-125.
10. Larouche J, Morais J, Picard M, et al. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol Ther. 1995;9:315-320.
11. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol. 1993;33:712-718.
12. Abdel-Alim AA, El-Shorbagi AN, Abdel-Moty SG, et al. Synthesis and anti-inflammatory testing of some new compounds incorporating 5-aminosalicylic acid (5-ASA) as potential prodrugs. Arch Pharm Res. 2005; 28:637-647.
13. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179-189.